Patients with anorexia nervosa | |||||
---|---|---|---|---|---|
Characteristic | Healthy controls n = 79 | At admission n = 149 | At discharge n = 130 | At 1-year follow-up n = 116 | At 2.5-year follow-up n = 76 |
Age, yr | 16.35 ± 1.93 | 15.32 ± 1.46 | 15.56 ± 1.51 | 16.3 ± 1.49 | 17.57 ± 1.54 |
BMI, kg/m2 | 21.25 ± 2.75 | 15.03 ± 1.28 | 18.08 ± 0.99 | 18.21 ± 1.69 | 19.26 ± 2.4 |
BMI-SDS | 0.02 ± 0.81 | −2.68 ± 0.91 | −0.96 ± 0.42 | −1.11 ± 0.76 | −0.83 ± 1.14 |
>10th age-adapted BMI percentile* | 100% | 3.35% | 83.7% | 68.42% | 71.05% |
Eating Disorder Inventory 2 score | 186.22 ± 44.19 | 261.41 ± 59.21 | 235.83 ± 61.27 | 256.05 ± 72.09 | 251.66 ± 63.14 |
Beck Depression Inventory II score | 5.07 ± 5.26 | 19.54 ± 10.38 | 10.46 ± 8.44 | 13.36 ± 11.06 | 12.63 ± 10.81 |
Spence Children’s Anxiety Scale score | 15.11 ± 7.7 | 22.53 ± 12.81 | 16.92 ± 11.85 | 18.28 ± 11.98 | 20.2 ± 14.91 |
Morgan–Russell Outcome Assessment Schedule score | – | 84.31 ± 25.11 | 97.47 ± 32.93 | 116.77 ± 28.86 | 125.09 ± 23.61 |
SIAB-EX total score | – | 63.74 ± 17.64 | 34.56 ± 14.42 | 40.57 ± 22.1 | 37.04 ± 24.19 |
Binge–purge subtype | – | 19.5% | 19.2% | 17.2% | 23.7% |
Taking SSRIs | – | 5% | 10% | 16% | 18% |
Taking olanzapine | – | 0% | 7.4% | 6% | 0% |
Menstruating† | – | 0% | 18.3% | 31.1% | 38.7% |
Taking hormonal contraception | – | 11.5% | 8.3% | 13.1% | 48.0% |
Serum BDNF, ng/mL | 14.08 ± 0.75 | 17.36 ± 6.57 | 18.42 ± 7.48 | 19.07 ± 7.59 | 20.84 ± 8.26 |
cBDNF | −0.44 ± 6.92 | −1.76 ± 6.24 | −0.31 ± 6.96 | 1.07 ± 7.11 | 2.8 ± 8.04 |
BDNF = brain-derived neurotrophic factor; BMI = body mass index; BMI-SDS = BMI standard deviation score (age-adapted BMI); cBDNF = BDNF corrected for age, storage time and batch effect; SIAB-EX = Structured Interview for Anorexia and Bulimia expert interview; SSRI = selective serotonin reuptake inhibitor.
Values are mean ± standard deviation or percent.
↵* Percentage of patients who had recovered a normal BMI.
↵† Percentage of patients with regular or irregular menstruation, excluding patients taking hormonal contraception.